Overview
- Provides a detailed description of biopharmaceuticals production as well as an overview of the field of algae-made biopharmaceuticals
- Analyzes and compares chloroplast expression approaches in terms of gene expression schemes, yields, and post-translational modifications
- The first comprehensive book in this field
Access this book
Tax calculation will be finalised at checkout
Other ways to access
Table of contents (9 chapters)
-
Front Matter
-
Back Matter
Keywords
About this book
This book constitutes a key reference on the use of algae in the biopharmaceuticals production field; providing an updated outlook on the achievements accomplished thus far and transmitting a prospective view for this biotechnological application.
This book provides a detailed description of the technology as well as an updated outlook of the strides achieved thus far in the field of algae-based biopharmaceuticals. Algae constitute attractive expression hosts for the production of recombinant proteins with medical applications. Among the features that make them attractive candidates are: low cost, fast growth, wide biosynthetic capacity, and absence of human pathogens; which constitute substantial advantages with respect to bacterial and mammalian systems.
First, the features of algae as convenient hosts for the production of BFs are analyzed in terms of production costs, biosynthetic capacity, and safety (Chapter 1). Second, the genetic engineering tools for algae-species are described. Nuclear and chloroplast-based expression approaches are analyzed and compared in terms of biosynthetic advantages, gene expression complexity, and DNA transfer approaches (Chapter 2). In the following sections, chapters 3 to 7, the state of the art on producing distinct types of BFs in algae species is presented. Although this book is mainly focused on BFs, considering that the production of compounds with health-promoting properties are achieved using genetically-engineered algae strains, chapter 8 deals with nutraceuticals. In the ninth chapter, the developments reported thus far are placed in perspective and challenges for the field are discussed. Critical future prospects comprise the following: optimizing large-scale production in bioreactors, implementing glycoengineering approaches, optimizing nuclear expression, exploring new approaches for oral delivery, and implementing regulatory frameworks to accomplish technology transferand regulatory approval of algae-made BFs.
Authors and Affiliations
About the author
Dr. Sergio Rosales-Mendoza is professor of Biotechnology and has worked in the area of biopharmaceuticals produced in low‐cost platforms for the past 10 years. Over his career, Dr. Rosales-Mendoza has published several scientific refereed articles in international high‐impact scientific journals.
Bibliographic Information
Book Title: Algae-Based Biopharmaceuticals
Authors: Sergio Rosales-Mendoza
DOI: https://doi.org/10.1007/978-3-319-32232-2
Publisher: Springer Cham
eBook Packages: Biomedical and Life Sciences, Biomedical and Life Sciences (R0)
Copyright Information: Springer International Publishing Switzerland 2016
Hardcover ISBN: 978-3-319-32230-8Published: 31 May 2016
Softcover ISBN: 978-3-319-81229-8Published: 30 May 2018
eBook ISBN: 978-3-319-32232-2Published: 21 May 2016
Edition Number: 1
Number of Pages: X, 166
Number of Illustrations: 25 b/w illustrations, 22 illustrations in colour
Topics: Plant Breeding/Biotechnology, Freshwater & Marine Ecology, Pharmaceutical Sciences/Technology, Plant Anatomy/Development